Tag: FEATURED

Draft FDA Guidance – Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction – Guidance for Industry

Released: January 7, 2025Level 1 GuidanceDraft This draft guidance document from the U.S. Food and Drug Administration (FDA) outlines recommendations for the development of drugs and biological products intended for weight reduction and maintenance in both adult and pediatric patients with obesity or overweight and related comorbidities. It provides information on clinical trial design, including subject populations, trial size and duration, and the assessment […]

Review Article – GLP-1-Based Therapies for Diabetes, Obesity and Beyond

by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8. Epub ahead of print. PMID: 40281304. This review article discusses GLP-1-based therapies, highlighting their effectiveness for managing type 2 diabetes and obesity, including well-known drugs like semaglutide and tirzepatide. The text details the evolution […]

Healthcare News – Cigna doubles down on GLP-1 support programs with 2 new launches

The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article focuses on Cigna’s strategies regarding the growing demand for GLP-1 weight loss medications. Cigna’s health services division, Evernorth, is launching two new support programs aimed at assisting patients and easing concerns for payers regarding the high […]

Breast Cancer Research – Can weight loss drugs prevent breast cancer recurrence?

That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm Researchers in Dallas are investigating the potential of weight loss medications, specifically a drug called tirzepatide, as a novel approach to reducing the risk of breast cancer recurrence in women who are […]

Journal Article – “Body Composition Metrics as a Determinant of Trastuzumab Deruxtecan Related Toxicity and Response”

Yaacobi Peretz, S., Kessner, R., Bar, Y. et al. Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response. npj Breast Cancer 11, 38 (2025). https://doi.org/10.1038/s41523-025-00754-7 This scientific article explores the connection between a patient’s body composition and their experience with the drug trastuzumab deruxtecan (T-DXd) for metastatic breast cancer. Using computed tomography scans to measure muscle and […]

Journal Article – “Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults”

by Jennifer H Hwang, DO; Neda Laiteerapong, MD; Elbert S. Huang, MD; David D. Kim, PhDJAMA Health Forum: 2025 Mar 7;6(3):e245586. doi: 10.1001/jamahealthforum.2024.5586. Published March 14, 2025 This research evaluates the cost-effectiveness of four different antiobesity medications compared to lifestyle modification alone for US adults. Using a microsimulation model, the study projected the lifetime health benefits and costs of these treatments for […]

News Article- Obesity drug coverage could lead to ‘substantial’ increase in Medicare spending

by Michael Monostra Fact Checked by Richard Smith from Endocrine Today/Healio NewsPublished April 25, 2025 According to findings from a microsimulation model, covering obesity medications under Medicare Part D is projected to significantly increase federal spending, estimated at $47.7 billion over ten years. While these drugs may reduce healthcare costs associated with obesity-related conditions, these savings are currently not […]

News Article – Maximizing Your Healthspan

American Heart Association by Laura Williamson, American Heart Association NewsPublished: January 14, 2025 The American Heart Association discusses healthspan, defining it as the number of years one lives free from significant chronic disease or disability, and contrasts it with life expectancy. It highlights the concerning trend of shrinking healthspans in the U.S. despite recent rebounds in […]